LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

NLRB Withdraws Unfair Labor Practices Claim Against Neogen

February 18, 2025 | Last Trade: US$5.60 0.04 -0.71

LANSING, Mich., Feb. 18, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today the National Labor Relations Board (NLRB) has withdrawn its unfair labor practices claim against the Company. The claim was withdrawn following a mutual agreement, with no admission of wrongdoing by Neogen.

In the coming weeks, Lansing warehouse shipping clerks and material handling employees will have the opportunity to vote in an election to determine whether they wish to unionize.

"At Neogen, we are dedicated to fostering a supportive and equitable workplace where employees feel valued and heard," said Amy Rocklin, Chief Legal and Compliance Officer. "We respect our employees' rights and we prioritize a positive work environment. Neogen remains committed to supporting our employees throughout this process and will continue to comply fully with all legal obligations related to the election."

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Contact
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page